

**IGHG1 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP11658c****Specification**

---

**IGHG1 Antibody (Center) Blocking peptide - Product Information**Primary Accession [P01857](#)**IGHG1 Antibody (Center) Blocking peptide - Additional Information****Other Names**

Ig gamma-1 chain C region, IGHG1

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**IGHG1 Antibody (Center) Blocking peptide - Protein Information****Name** IGHG1 {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.13}**Function**

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins- secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:<a href="http://www.uniprot.org/citations/22158414" target="\_blank">22158414</a>, PubMed:<a href="http://www.uniprot.org/citations/20176268" target="\_blank">20176268</a>). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:<a href="http://www.uniprot.org/citations/17576170" target="\_blank">17576170</a>, PubMed:<a href="http://www.uniprot.org/citations/20176268" target="\_blank">20176268</a>). Mediates IgG effector functions on monocytes triggering ADCC of virus- infected cells.

**Cellular Location**

[Isoform 1]: Secreted

**IGHG1 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**IGHG1 Antibody (Center) Blocking peptide - Images****IGHG1 Antibody (Center) Blocking peptide - Background**

The specific function of the protein remains unknown.